200 related articles for article (PubMed ID: 27696778)
1. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.
Tweehuysen L; van den Ende CH; Beeren FM; Been EM; van den Hoogen FH; den Broeder AA
Arthritis Rheumatol; 2017 Feb; 69(2):301-308. PubMed ID: 27696778
[TBL] [Abstract][Full Text] [Related]
2. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases.
Souto A; Maneiro JR; Gómez-Reino JJ
Rheumatology (Oxford); 2016 Mar; 55(3):523-34. PubMed ID: 26490106
[TBL] [Abstract][Full Text] [Related]
3. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.
Schlager L; Loiskandl M; Aletaha D; Radner H
Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305
[TBL] [Abstract][Full Text] [Related]
4. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
Iwamoto T; Ikeda K; Hosokawa J; Yamagata M; Tanaka S; Norimoto A; Sanayama Y; Nakagomi D; Takahashi K; Hirose K; Sugiyama T; Sueishi M; Nakajima H
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1576-81. PubMed ID: 24515410
[TBL] [Abstract][Full Text] [Related]
5. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
[TBL] [Abstract][Full Text] [Related]
6. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
[TBL] [Abstract][Full Text] [Related]
7. Biologic discontinuation studies: a systematic review of methods.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Mar; 73(3):595-9. PubMed ID: 23723316
[TBL] [Abstract][Full Text] [Related]
8. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
Tanaka Y; Hirata S
Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
[TBL] [Abstract][Full Text] [Related]
9. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Jan; 73(1):e5. PubMed ID: 24152418
[No Abstract] [Full Text] [Related]
10. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
[TBL] [Abstract][Full Text] [Related]
11. Current concepts in the management of rheumatoid arthritis.
Tanaka Y
Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
[TBL] [Abstract][Full Text] [Related]
12. Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al.
van der Maas A; van Herwaarden N; den Broeder AA
Ann Rheum Dis; 2014 Jan; 73(1):e4. PubMed ID: 24078674
[No Abstract] [Full Text] [Related]
13. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
[TBL] [Abstract][Full Text] [Related]
14. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
15. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review.
Letarouilly JG; Salmon JH; Flipo RM
Expert Opin Drug Saf; 2021 Sep; 20(9):1087-1094. PubMed ID: 33926364
[No Abstract] [Full Text] [Related]
18. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
19. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
20. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]